Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2017

Open Access 01-12-2017 | Research article

The effectiveness of creatine treatment for Parkinson’s disease: an updated meta-analysis of randomized controlled trials

Authors: Jia-Jie Mo, Lin-Ying Liu, Wei-Bin Peng, Jie Rao, Zhou Liu, Li-Li Cui

Published in: BMC Neurology | Issue 1/2017

Login to get access

Abstract

Background

The effectiveness of creatine in treating Parkinson’s disease (PD) has not been conclusively determined. Therefore, we performed a meta-analysis to address this issue.

Methods

The Cochrane Central Register of Controlled Trials, PUBMED, EMBASE, and other databases were searched, and outcomes measured by the Total Unified Parkinson’s Disease Rating Scale (UPDRS) and the Schwab & England Scale were analyzed.

Results

Five randomized controlled trials (RCTs) were selected, and 1339 participants were included in the analysis. There were no significant differences between the control and treatment groups in the total, mental, activities of daily living (ADL), or motor UPDRS scores, but an improvement in Schwab & England Scale scores was observed.

Conclusions

Creatine has no observed benefit in PD patients, although more correlated studies are still needed.
Literature
1.
2.
Simon DK, Wu C, Tilley BC, Wills AM, Aminoff MJ, Bainbridge J, et al. Caffeine and progression of Parkinson disease: a deleterious interaction with Creatine. Clin Neuropharmacol. 2015;38(5):163–9.CrossRefPubMedPubMedCentral
3.
Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology. 2003;60(8):1234–40.CrossRefPubMed
4.
Comi C, Magistrelli L, Oggioni GD, Carecchio M, Fleetwood T, Cantello R, et al. Peripheral nervous system involvement in Parkinson's disease: evidence and controversies. Parkinsonism Relat Disord. 2014;20(12):1329–34.CrossRefPubMed
5.
Lewitt PA. Clinical trials of neuroprotection for Parkinson's disease. Neurology. 2004;63(2):23–31.CrossRef
6.
Takubo H, Shimoda-Matsubayashi S, Mizuno Y. Serum creatine kinase is elevated in patients with Parkinson's disease: a case controlled study. Parkinsonism Relat Disord. 2003;9(Suppl 1):S43–6.CrossRefPubMed
7.
Wyss M, Schulze A. Health implications of creatine: can oral creatine supplementation protect against neurological and atherosclerotic disease? Neuroscience. 2002;112(2):243–60.CrossRefPubMed
8.
Tarnopolsky MA. Potential benefits of creatine monohydrate supplementation in the elderly. Curr Opin Clin Nutr Metab Care. 2000;3(6):497–502.CrossRefPubMed
9.
Shimoda-Matsubayashi S, Yagi K, Tanabe H. [the elevation of serum creatine kinase in the course of Parkinson disease.--in relation to malignant syndrome]. Rinsho shinkeigaku =. Clinical neurology. 1996;36(8):935–9.PubMed
10.
Bender A, Klopstock T. Creatine for neuroprotection in neurodegenerative disease: end of story? Amino Acids. 2016;48(8):1–12.CrossRef
11.
Bereket-Yucel S. Creatine supplementation alters homocysteine level in resistance trained men. J Sports Med Phys Fitness. 2015;55(4):313–9.PubMed
12.
Lawler JM, Barnes WS, Wu G, Song W, Demaree S. Direct antioxidant properties of creatine. Biochem Biophys Res Commun. 2002;290(1):47–52.CrossRefPubMed
13.
Sakly G, Hellara O, Trabelsi A, Dogui M. Reversible peripheral neuropathy induced by vitamin B12 deficiency. Neurophysiol Clin. 2005;35(5–6):149–53.CrossRefPubMed
14.
Puri V, Chaudhry N, Goel S, Gulati P, Nehru R, Chowdhury D. Vitamin B12 deficiency: a clinical and electrophysiological profile. Electromyogr Clin Neurophysiol. 2005;45(5):273–84.PubMed
15.
Allen PJ. Creatine metabolism and psychiatric disorders: does creatine supplementation have therapeutic value? Neurosci Biobehav Rev. 2012;36(5):1442–62.CrossRefPubMedPubMedCentral
16.
17.
Hass CJ, Collins MA, Juncos JL. Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial. Neurorehabil Neural Repair. 2007;21(2):107–15.CrossRefPubMed
18.
Li Z, Wang P, Yu Z, Cong Y, Sun H, Zhang J, et al. The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinson's disease. Eur Neurol. 2015;73(3–4):205–11.CrossRefPubMed
19.
Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015;313(6):584–93.CrossRefPubMed
20.
NINDS. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol. 2008;31(3):141–50.CrossRef
21.
Bender A, Koch W, Elstner M, Schombacher Y, Bender J, Moeschl M, et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology. 2006;67(7):1262–4.CrossRefPubMed
22.
NINDS. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66(5):664–71.CrossRef
23.
Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society task force guidelines. Mov Disord. 2012;27(3):349–56.CrossRefPubMedPubMedCentral
24.
Higgins J, Green SE. Cochrane Handbook for systematic reviews of interventions Version 5.1.0. The Cochrane collaboration (Eds); 2011. p. 202–6.
25.
Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27(5):335–71.CrossRefPubMed
26.
27.
Bloom MZ. NIH announces phase III clinical trial of creatine for Parkinson's disease. Consult Pharm. 2007;22(5):378.PubMed
28.
Xiao Y, Luo M, Luo H, Wang J. Creatine for Parkinson's disease. Cochrane Database Syst. Rev. 2014; 2014(6):Cd009646.
29.
Joncquel-Chevalier Curt M, Voicu PM, Fontaine M, Dessein AF, Porchet N, Mention-Mulliez K, et al. Creatine biosynthesis and transport in health and disease. Biochimie. 2015;119:146–65.CrossRefPubMed
30.
Ostojic SM, Ostojic J, Drid P, Vranes M. Guanidinoacetic acid versus creatine for improved brain and muscle creatine levels: a superiority pilot trial in healthy men. Appl Physiol Nutr Metab = Physiologie appliquee, nutrition et metabolisme. 2016;41(9):1005–7.CrossRefPubMed
31.
Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry. 2005;10(10):900–19.CrossRefPubMed
Metadata
Title
The effectiveness of creatine treatment for Parkinson’s disease: an updated meta-analysis of randomized controlled trials
Authors
Jia-Jie Mo
Lin-Ying Liu
Wei-Bin Peng
Jie Rao
Zhou Liu
Li-Li Cui
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2017
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-017-0885-3

Other articles of this Issue 1/2017

BMC Neurology 1/2017 Go to the issue

Case report

Conjugal amyotrophic lateral sclerosis: a case report from Scotland

Research article

Co-morbidity and polypharmacy in Parkinson’s disease: insights from a large Scottish primary care database

Case report

Secondary pallidonigral degeneration mimicking recurrent acute stroke in clinical presentation and magnetic resonance imaging: a case report

Study protocol

The Comprehensive Post-Acute Stroke Services (COMPASS) study: design and methods for a cluster-randomized pragmatic trial

Research article

Ultra high-field SWI of the substantia nigra at 7T: reliability and consistency of the swallow-tail sign

Study protocol

Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy